CUBAN NEWS COVID-19
CUBA reports about the development of phase III clinical trials and intervention studies of Soberana 02 and Abdala vaccines,which are among the vaccines being developed in the world in stage III of trials.
SOBERANA 02 PHASE III CLINICAL TRIAL:
Total subjects to be vaccineated: 44,010. Vaccinated with first dose: 44,010 (100%)
ABDALA PHASE III CLINICAL TRIAL:
Total subjects to be vaccinated: 48,000. First dose vaccinated: 48,000 (100 %)
We are currently in the process of applying the second dose of both vaccine candidates in the study population.
The population controlled intervention trial with the vaccine candidate SOBERANA 02 in Havana also continues. This trial (distributed in three stages), includes 150,000 volunteers belonging to the risk group of health workers, the biopharmaceutical sector of Havana and other segments defined by the Ministry of Public Health.
No later than August, Cuba will have vaccines for its entire population
The production systems have been structured so that, when the safety and efficacy of the vaccine candidates under study is demonstrated, to have millions of doses.
Within this strategy Cuba also taken into account the appearance of new variants of the virus, that is why a group of researchers from the Pedro Kourí Institute of Tropical Medicine (IPK), from the University of Informatics Sciences (UCI) and from BioCubaFarma, they study and model the new mutations that are appearing in the world, and others that could arise.
Pan-Corona: Anti-SARS-CoV-2 vaccine developed by Cuba and China.
Scientists from Cuba and China are working together to develop Pan?Corona, a vaccine proposal that they intend to be effective against different strains of the SARS?CoV?2 coronavirus and prevent Covid?19.